Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000905148-25-003402
Filing Date
2025-09-24
Accepted
2025-09-24 17:11:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 28165
2 jointfilingagreement.htm EX-99.1 8159
  Complete submission text file 0000905148-25-003402.txt   38307
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Subject) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-51477 | Film No.: 251339414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901
Business Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

EIN.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G